PHYSICAL CONDITIONING AND CORE STRENGTH TRAINING IN FEMALE COLLEGE AEROBICS GYMNASTICS ATHLETES

ABSTRACT Introduction Competitive aerobics is a high-level sport that has the achievement of the championship and the pursuit of excellence as its primary objective. Strengthening the core is an integral part of sports training. Personalized core strength training for athletes in aerobics gymnastics is critical for sports success. Objective To study the core strength training of university aerobics gymnastics athletes exploring its effects on physical conditioning and skills. Methods After the literature survey, mathematical statistics discuss core strength training methods focused on female aerobics college athletes. Results Women’s aerobics athletes’ static squats, full squats with weights, and load intensity directly interfere with the difficulty and performance of aerobic movements. This experiment’s organizing hip supine, push-up, and abdominal control are very significant. Conclusion Core strength training helps improve the physical conditioning of female college aerobics athletes. Evidence Level II; Therapeutic Studies – Investigating the results.</div

Additional file 1 of The effect of Baduanjin exercise on health-related physical fitness of college students: study protocol for a randomized controlled trial

SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 91 kb

Additional file 1 of Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner

Supplementary Material 1: Supplementary Fig. 1. EZH2-related genes in tumors provided by bioinformatics analysis based on TCGA-BRCA using STRING, and metascape databas

Establishment of the risk score.

In the TCGA cohort, BC patients were distributed into different risk groups (A). Survival status of BC patients in different risk groups (B). The survival rate of the high-risk BC patients was worse than that of the low-risk patients (C). AUCs of the ROC curves were shown (D). In the verification cohort of the GEO, BC patients were distributed into different risk groups (E). Survival status of BC patients in different risk groups (F). The survival rate of the high-risk BC patients was worse than that of the low-risk patients (G). AUCs of the ROC curves were shown (H) TCGA, the Cancer Genome Atlas; GEO, Gene Expression Omnibus; AUC, area under the ROC curve; OS, overall survival; ROC, receiver operating characteristics; BC, bladder cancer.</p

The relationship between HDAC9 expression and TILs.

The first six TILs with the strongest correlation with HDAC9 in BC were visualized (A-F). HDAC9, histone deacetylase 9; TILs, tumor-infiltrating lymphocytes; BC, bladder cancer. (TIF)</p

Stromal cells in BC patients based on the xCell algorithm.

Results indicated that enrichment of signatures of eight stromal cells [adipocytes (A), chondrocytes (B), endothelial cells (C), fibroblasts (D), ly endothelial cells (E), MSCs (F), myocytes (G) and smooth muscle (H)] from the TME in the high-risk group. BC, bladder cancer; MSCs, mesenchymal stem cells; ly endothelial cells, lymphatic endothelial cells; TME, tumor microenvironment; P. adj, P. adjust.</p

The coefficients of included genes.

(DOCX)</p

The relationship between genes included in the risk signature and TME.

Correlation analysis was performed to further understand connections between genes included in the risk signature and TME. The relevant results were visualized via a heatmap. TME, tumor microenvironment; *, P. adjust (TIF)</p

Risk score and drug sensitivity.

Cisplatin (A) and docetaxel (B) exhibited higher IC50 values in low-risk patients; thus, the high-risk group was more sensitive to cisplatin and docetaxel. Methotrexate (C) and gemcitabine (D) exhibited a higher IC50 in high-risk BC patients; thus, low-risk BC patients were more sensitive to methotrexate and gemcitabine. However, there were no significant differences between other chemotherapy drugs (paclitaxel and doxorubicin) and the risk score (E-F). The CR/PR rate in low-risk patients was higher than that in high-risk patients (G), indicating more significant immunotherapy benefits for low-risk patients. IC50, half-maximal inhibitory concentration; SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response; BC, bladder cancer; *, P <0.05; ****, P < 0.0001.</p

Characteristics of the BC patients obtained from the GEO database.

Characteristics of the BC patients obtained from the GEO database.</p